A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
- PMID: 24251159
- PMCID: PMC3830305
- DOI: 10.4103/2230-8210.119572
A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
Abstract
New-onset diabetes after transplantation (NODAT) is frequently encountered after kidney transplant. In the present study, we retrospectively evaluated the safety and efficacy of linagliptin monotherapy in 21 renal transplant recipients in a real world setting. We found linagliptin monotherapy is effective for glycemic control in NODAT, even on glucocorticoids and standard dose of tacrolimus. There was no alteration of tacrolimus drug levels or estimated glomerular filtration rate (eGFR) and minimal side effects, including weight gain and hypoglycemia. Well-designed, powered randomized controlled of antiglycemic agents in NODAT are needed.
Keywords: Linagliptin; new-onset diabetes after transplantation; renal transplant.
Conflict of interest statement
References
-
- Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, et al. Transplantation 2003. Vol. 75. Barcelona, Spain: 2003. Feb 19, International Expert Panel. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting; pp. SS3–24. - PubMed
-
- Sulanc E, Lane JT, Puumala SE, Groggel GC, Wrenshall LE, Stevens RB. New-onset diabetes after kidney transplantation: An application of 2003 international guidelines. Transplantation. 2005;80:945–52. - PubMed
-
- Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant. 2011;11:1376–81. - PubMed
-
- Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38:667–78. - PubMed
-
- Graefe-Mody U, Friedrich C, Port A. Effect of renal impairment on the pharmacokineticsof the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13:939–46. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous